Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Maximilian J. Hochmair; Mojca Unk; Jelena Spasic; Timur Cerić; Assia Konsoulova; Mircea Dediu; Krisztina Bogos; Alinta Hegmane; Kersti Oselin; Marko Stojiljkovic; Tina Roblek; Marko Jakopovic

doi:10.1186/s12919-023-00287-6

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Maximilian J. Hochmair
, Mojca Unk
, Jelena Spasic
, Timur Cerić
, Assia Konsoulova
, Mircea Dediu
, Krisztina Bogos
, Alinta Hegmane
, Kersti Oselin
, Marko Stojiljkovic
, Tina Roblek
, Marko Jakopovic^*

^*Corresponding author for this work

Klinik Floridsdorf
Institute of Oncology Ljubljana
Institute for Oncology and Radiology of Serbia
Sarajevo University Clinical Center
National Oncology Center Bulgaria
Sanador Oncology Center Bucharest
National Koranyi Institute for Pulmonology
Riga East University Hospital
North Estonia Medical Centre
Takeda d.o.o.
Takeda Pharmaceuticals d.O.O.
University of Zagreb

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among them, EGFR exon 20 insertion mutations, constituting 0.3–2.2% of NSCLC cases, rank as the third most common EGFR alteration after exon 19 deletions and the L858R point mutation in exon 21, also known as “typical” EGFR alterations. Recent advancements in understanding the molecular pathogenesis of NSCLC have led to significant breakthroughs in targeted therapies, revolutionizing treatment options for patients with specific genetic alterations.

Original language	English
Article number	2
Journal	BMC Proceedings
Volume	18
DOIs	https://doi.org/10.1186/s12919-023-00287-6
Publication status	Published - Jan 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 10 Reduced Inequalities

Keywords

Diagnostic challenges
EGFR exon 20 insertion mutations
Healthcare disparities in Central and Eastern Europe
NSCLC treatment
Next-generation sequencing
Targeted therapies

Access to Document

10.1186/s12919-023-00287-6

Cite this

Hochmair, M. J., Unk, M., Spasic, J., Cerić, T., Konsoulova, A., Dediu, M., Bogos, K., Hegmane, A., Oselin, K., Stojiljkovic, M., Roblek, T., & Jakopovic, M. (2024). Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability. BMC Proceedings, 18, Article 2. https://doi.org/10.1186/s12919-023-00287-6

@article{2682ecfbddf54ecc84ae89ec44a53298,

title = "Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability",

abstract = "Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85\% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among them, EGFR exon 20 insertion mutations, constituting 0.3–2.2\% of NSCLC cases, rank as the third most common EGFR alteration after exon 19 deletions and the L858R point mutation in exon 21, also known as “typical” EGFR alterations. Recent advancements in understanding the molecular pathogenesis of NSCLC have led to significant breakthroughs in targeted therapies, revolutionizing treatment options for patients with specific genetic alterations.",

keywords = "Diagnostic challenges, EGFR exon 20 insertion mutations, Healthcare disparities in Central and Eastern Europe, NSCLC treatment, Next-generation sequencing, Targeted therapies",

author = "Hochmair, \{Maximilian J.\} and Mojca Unk and Jelena Spasic and Timur Ceri{\'c} and Assia Konsoulova and Mircea Dediu and Krisztina Bogos and Alinta Hegmane and Kersti Oselin and Marko Stojiljkovic and Tina Roblek and Marko Jakopovic",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2024",

month = jan,

doi = "10.1186/s12919-023-00287-6",

language = "English",

volume = "18",

journal = "BMC Proceedings",

issn = "1753-6561",

publisher = "BioMed Central Ltd",

}

TY - JOUR

T1 - Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe

T2 - reimbursement, diagnostic procedures, and treatment availability

AU - Hochmair, Maximilian J.

AU - Unk, Mojca

AU - Spasic, Jelena

AU - Cerić, Timur

AU - Konsoulova, Assia

AU - Dediu, Mircea

AU - Bogos, Krisztina

AU - Hegmane, Alinta

AU - Oselin, Kersti

AU - Stojiljkovic, Marko

AU - Roblek, Tina

AU - Jakopovic, Marko

PY - 2024/1

Y1 - 2024/1

N2 - Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among them, EGFR exon 20 insertion mutations, constituting 0.3–2.2% of NSCLC cases, rank as the third most common EGFR alteration after exon 19 deletions and the L858R point mutation in exon 21, also known as “typical” EGFR alterations. Recent advancements in understanding the molecular pathogenesis of NSCLC have led to significant breakthroughs in targeted therapies, revolutionizing treatment options for patients with specific genetic alterations.

AB - Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among them, EGFR exon 20 insertion mutations, constituting 0.3–2.2% of NSCLC cases, rank as the third most common EGFR alteration after exon 19 deletions and the L858R point mutation in exon 21, also known as “typical” EGFR alterations. Recent advancements in understanding the molecular pathogenesis of NSCLC have led to significant breakthroughs in targeted therapies, revolutionizing treatment options for patients with specific genetic alterations.

KW - Diagnostic challenges

KW - EGFR exon 20 insertion mutations

KW - Healthcare disparities in Central and Eastern Europe

KW - NSCLC treatment

KW - Next-generation sequencing

KW - Targeted therapies

UR - https://www.scopus.com/pages/publications/85182672915

U2 - 10.1186/s12919-023-00287-6

DO - 10.1186/s12919-023-00287-6

M3 - Article

AN - SCOPUS:85182672915

SN - 1753-6561

VL - 18

JO - BMC Proceedings

JF - BMC Proceedings

M1 - 2

ER -

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this